Get the Stockscreener App
1.01
0.00%
0.00
After Hours:
1.01
Pds Biotechnology Corporation stock is traded at $1.01, with a volume of 279.95K.
It is up +0.00% in the last 24 hours and down -18.55% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$1.01
Open:
$1.04
24h Volume:
279.95K
Relative Volume:
0.58
Market Cap:
$47.50M
Revenue:
-
Net Income/Loss:
$-40.56M
P/E Ratio:
-0.8632
EPS:
-1.17
Net Cash Flow:
$-35.28M
1W Performance:
-3.81%
1M Performance:
-18.55%
6M Performance:
-15.13%
1Y Performance:
-73.56%
1-Day Range:
$1.00
$1.04
1-Week Range:
$1.00
$1.08
52-Week Range:
$0.8505
$4.29
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.01 | 47.50M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
What’s the recovery path for long term holders of PDS Biotechnology CorporationJuly 2025 Levels & Real-Time Stock Entry Alerts - newser.com
Is PDS Biotechnology Corporation stock undervalued vs historical averagesJuly 2025 PostEarnings & Weekly Breakout Opportunity Watchlist - newser.com
How to integrate PDS Biotechnology Corporation into portfolio analysis toolsQuarterly Investment Review & Real-Time Market Sentiment Alerts - newser.com
Is PDS Biotechnology Corporation stock a safe investment in uncertain marketsJuly 2025 Trade Ideas & Fast Gaining Stock Reports - newser.com
Momentum divergence signals in PDS Biotechnology Corporation chartEarnings Trend Report & Weekly High Return Forecasts - newser.com
Using data filters to optimize entry into PDS Biotechnology CorporationWeekly Trade Report & Entry Point Confirmation Alerts - newser.com
What technical models suggest about PDS Biotechnology Corporation’s comebackJuly 2025 Pullbacks & Weekly High Potential Stock Alerts - newser.com
Key resistance and support levels for PDS Biotechnology Corporation2025 Fundamental Recap & Capital Protection Trade Alerts - newser.com
What valuation multiples suggest for PDS Biotechnology Corporation stockQuarterly Profit Summary & Detailed Earnings Play Strategies - newser.com
PDS Biotechnology Reports Promising Phase 2 Trial Results - MSN
Applying Elliott Wave Theory to PDS Biotechnology CorporationTrade Exit Summary & Safe Capital Growth Tips - newser.com
Critical Comparison: PDS Biotechnology (NASDAQ:PDSB) and Femasys (NASDAQ:FEMY) - Defense World
Custom strategy builders for tracking PDS Biotechnology CorporationIPO Watch & Target Return Focused Picks - newser.com
Published on: 2025-09-19 23:06:32 - newser.com
PDS Biotechnology Corporation stock volume spike explained2025 Institutional Moves & High Yield Stock Recommendations - newser.com
Using portfolio simulators with PDS Biotechnology Corporation includedPortfolio Update Report & Technical Confirmation Alerts - newser.com
Pattern recognition hints at PDS Biotechnology Corporation upside2025 Winners & Losers & Safe Swing Trade Setup Alerts - newser.com
Volatility clustering patterns for PDS Biotechnology CorporationPortfolio Return Report & AI Powered Trade Plan Recommendations - newser.com
Published on: 2025-09-19 03:12:27 - خودرو بانک
Chart based exit strategy for PDS Biotechnology CorporationJuly 2025 Spike Watch & Daily Oversold Bounce Ideas - newser.com
PDS Biotech reports 29.5-month survival in head and neck cancer trial - Investing.com Australia
PDS Biotech Sets Significant Benchmark in Head and Neck - GlobeNewswire
29.5-Month Survival Breakthrough: PDS Biotech's Cancer Drug Shows Nearly 3x Better Results Than Current Treatment - Stock Titan
Market Review: Can OSR Holdings Inc Equity Warrant continue delivering strong returnsMarket Performance Summary & Free Daily Entry Point Trade Alerts - khodrobank.com
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):